Columbus Circle Capital Corp II
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gary Quin
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 3 Columbus Circle New York City NY United States of America
- IPO Date
- Feb 11, 2026
- CIK
- 0001837412
- Website
- ii.cmlifesciencesspac.com
- Similar Companies
- Business
- CM Life Sciences II Inc. (CMIIU) is a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting companies in the life sciences sector including therapeutics, diagnostics, and research tools. The company offers no specific products or services beyond its SPAC structure, which facilitates investment opportunities through its public listing and trust account management for potential targets; it does not manufacture, sell, or provide operational goods or services. Headquartered in New York, New York, CM Life Sciences II Inc. was formed in 2020 as part of the series of life sciences-focused SPACs sponsored by Casdin Capital and Corvex Management. The company operates principally in the United States with a focus on North American life sciences firms as merger targets, serving institutional and accredited investors as its primary customer base. No major recent partnerships, funding rounds, acquisitions, new product launches, strategic shifts, expansions, name changes, or operational changes have been publicly reported for the company within the last 1-2 years.
Columbus Circle Capital Corp II Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 27, 2026
Columbus Circle Capital Corp. II and Cohen & Company Inc. Announce Completion of $230,000,000 Initial Public Offering
Columbus Circle Capital Corp II Announces Pricing of $200,000,000 Initial Public Offering
U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
ARK Investment Leans Into Biotech and Telecom Holdings
SomaLogic Customizable Protein Panels With Industry-Leading 7,000-Plex Assay Now Available
SomaLogic Latest to Take SPAC Route to Public Markets
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering